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Abstract
Background:  Guidelines published in major medical journals are very influential in determining
clinical practice. It would be essential to evaluate whether conflicts of interests are disclosed in
these publications. We evaluated the reporting of conflicts of interest and the factors that may
affect such disclosure in a sample of 191 guidelines on therapeutic and/or preventive measures
published in 6 major clinical journals (Annals of Internal Medicine, BMJ, JAMA, Lancet, New England
Journal of Medicine, Pediatrics) in 1979, 1984, 1989, 1994 and 1999.
Results:  Only 7 guidelines (3.7%) mentioned conflicts of interest and all were published in 1999
(17.5% (7/40) of guidelines published in 1999 alone). Reporting of conflicts of interest differed
significantly by journal (p=0.026), availability of disclosure policy by the journal (p=0.043), source
of funding (p < 0.001) and number of authors (p=0.004). In the entire database of 191 guidelines, a
mere 18 authors disclosed a total of 24 potential conflicts of interest and most pertained to minor
issues.
Conclusions:  Despite some recent improvement, reporting of conflicts of interest in clinical
guidelines published in influential journals is largely neglected.
Background
Guidelines have assumed a major role in forming practi-
tioner and patient decisions about appropriate health
care [1]. It is important that such efforts are not affected
by conflicts of interest and that guidelines are transpar-
ent to such potential conflicts. This is even more signifi-
cant for clinical guidelines published in influential
medical journals that are likely to have a major impact
upon therapeutic and preventive clinical care and public
health worldwide. However, there has been no study of
the reporting of conflicts of interest in guidelines pub-
lished in medical journals. We undertook an evaluation
of this issue in a sample of publications of clinical guide-
lines.
Published: 4 June 2001
BMC Medical Research Methodology 2001, 1:3
This article is available from: http://www.biomedcentral.com/1471-2288/1/3
(c) 2001 Papanikolaou et al, licensee BioMed Central Ltd.
Received: 5 March 2001
Accepted: 4 June 2001BMC Medical Research Methodology (2001) 1:3 http://www.biomedcentral.com/1471-2288/1/3
Materials and Methods
Our study evaluated 6 prestigious medical journals that
are likely to publish influential clinical guidelines. The
journals were selected so as to include the 4 most exten-
sively-cited clinical medicine interdisciplinary journals,
as well as the most extensively-cited adult internal med-
icine journal and the most extensively-cited pediatric
medicine journal according to the Institute of Scientific
Information Journal Citation Report. Each selected jour-
nal received more than 20,000 citations in 1999. Thus
we hand-searched the Annals of Internal Medicine, Brit-
ish Medical Journal (BMJ), Journal of the American
Medical Association (JAMA), Lancet, New England
Journal of Medicine and Pediatrics for guidelines pub-
lished during 1979, 1984, 1989, 1994 and 1999. The ap-
preciation of conflicts of interest has changed over the
last 20 years and increasingly more strict policies have
been adopted, especially in the 1990s. We aimed to eval-
uate whether this change is also reflected in a secular
trend in the reporting of conflicts of interests in guideline
publications. Therefore, we sampled guidelines across 5-
year intervals to cover a 20-year period. We preferred
hand searching rather than computerized searches in an
attempt to minimize loss of retrievals due to incomplete
computerized coding. Two investigators independently
hand-searched the pertinent volumes. Discrepancies
were solved by a third investigator to reach consensus.
In order to reduce subjective interpretation of what con-
stitutes a guideline publication we developed strict eligi-
bility criteria. Eligible for the study were all articles that
(I) contained in their titles, heading or abstracts (or in-
troductory / summary paragraph when an abstract was
missing) key words that were characteristic of guidelines
("guidelines" or "recommendations", "consensus [panel-
statement-conference]", "clinical synthesis conference",
"guidance", "policy statement", "practice parameter" and
"position [paper-article-statement]"; and (II) had main
focus on preventive and /or therapeutic interventions in-
cluding health care delivery. We excluded papers where
the main focus was on descriptive epidemiology, re-
search design, diagnosis (diagnostic performance rather
than clinical impact of diagnostic methods), risk assess-
ment, legal issues, biology and/or pathophysiology. We
specifically excluded editorials, commentaries, original
randomized controlled trials, as well as systematic re-
views and meta-analyses unless they were part of the
guideline. Both full-length and shortened versions qual-
ified, but comments and discussion items concerning
guidelines were excluded. The last search for eligible
guidelines was performed in mid-October 1999.
Data extraction, including journal, year, main subject fo-
cus, main country of origin, authorship, type(s) of inter-
ventions and funding, was performed on standardized
forms. We also recorded whether conflicts of interest
were mentioned at all, and if so, how much space was giv-
en for such disclosures. The amount of space given for
conflict disclosure does not necessarily guarantee the
completeness of disclosure or the quality of the conveyed
information, but it can be used as a surrogate of the im-
portance given to this information. This parameter has
been previously used for other aspects of reporting in
journal publications [2]. Finally, we recorded the nature
of specific disclosed conflicts. We considered all reported
conflicts of interest, financial and non-financial, that
were judged to be relevant for publication by each jour-
nal. For each selected journal we examined the instruc-
tions to the authors over the last 20 years to examine if
and when specific disclosure policies were available for
conflicts of interest.
Using the Fisher's exact test we evaluated whether there
were significant associations between characteristics of
guidelines and the reporting of conflicts of interest. Anal-
yses were conducted in SPSS 9.0 (SPSS Inc, Chicago, IL).
P-values are two-tailed.
Results
We recovered 191 publications of eligible guidelines (ta-
ble 1). All the 6 selected journals specifically state in their
current instructions to the authors that potential con-
flicts of interest should be declared, and have imple-
mented various conflict of interest policies. Guidelines
have not been specifically excluded from conflict disclo-
sure in any of the 6 journals. All 1999 and 1994 publica-
tions in these journals were subject to conflict disclosure
policies. In addition, such policies existed also by 1989
for JAMA, Pediatrics and New England Journal of Med-
icine.
Only 7 guidelines (3.7%) disclosed potential conflicts of
interest (table 1). The disclosure rate was 6.1% when es-
timated on the basis of the 115 guidelines published when
specific disclosure policies were in place. All disclosures
had been made in 1999 and for this year the disclosure
percentage was 17.5% (7/40). Reporting was also related
to specific journals (p=0.026), but the rate of disclosure
was very low even in the journal with the highest disclo-
sure rate (JAMA, 4/35 [11.4%]). The country of origin,
focus (therapy, prevention or both), group authorship
and emphasis on medication vs. other interventions
were not related to reporting of conflicts of interest
(p=1.00, 0.14, 1.00 and 1.00, respectively) suggesting the
deficiency is universal. Guidelines funded mostly by the
government, universities or major professional organi-
zations almost never reported on potential conflicts of
interest while guidelines funded by private or mixed
sources were more likely to disclose potential conflicts (p
< 0.001). Among guidelines where specific authors as-BMC Medical Research Methodology (2001) 1:3 http://www.biomedcentral.com/1471-2288/1/3
sumed primary responsibility for writing the manu-
script, reporting of conflicts of interest was more
common when there were more authors (p=0.004) (ta-
ble 1).
Further analysis revealed that all guidelines reporting
conflicts of interest dedicated less than 1/20 of a page for
this reason and less than 1/100 of the total length of the
article - with one exception where disclosure took 13
lines to report. In the entire database of 191 guidelines, a
mere 18 authors disclosed a total of 24 potential conflicts
of interest (table 2). The majority of the alluded items of
conflict were for relatively minor issues (such as travel
fees, speaker funds and consultation) while no author
disclosed possessing stock in a company.
Sixty guidelines (27 of them published under explicit
journal disclosure policies and 11 published in 1999)
mentioned either specific authors or identified individu-
als within a panel who assumed responsibility for writing
the manuscript. In total, 242 authors were listed in these
guidelines (139 publishing under explicit journal disclo-
sure policies and 79 in 1999 alone). Of those, only 15 au-
thors disclosed conflicts of interest. The percentage of
disclosing authors is 6.2% based on all years, 10.8%
based on publications under explicit journal disclosure
policies, and 19.0% based on 1999 alone. Panels of ex-
perts authored the other 131 guidelines, often with doz-
ens of listed members or without detailed listing of
contributors. In all these group-authored guidelines,
only 3 members of one single panel disclosed conflicts of
interest.
Discussion
Our study revealed that reporting of conflicts of interest
in guidelines of healthcare interventions is probably
largely neglected despite some recent improvement.
Even in 1999, only 1 out of 6 clinical guidelines disclosed
conflicts of interest. Reporting varied by journal. A re-
cent study has shown that 50% of US medical journals
with a circulation more than 1000 copies per issue (in-
cluding, of course, all journals we searched in our study)
have written policies regarding conflicts of interest [3,4].
Table 1: Characteristics of practice guidelines: reporting of con-
flicts of interest.
Conflicts of 
interest 
reported 
Conflicts of 
interest not 
reported
Exact 
p-value
 
N = 7 N = 184
Journal NEJM 0 7 0.026
JAMA 4 31
Lancet 0 9
Annals 2 31
BMJ 1 17
Pediatrics 0 89
Year 1979 0 22 <0.001
1984 0 40
1989 0 47
1994 0 42
1999 7 33
Disclosure policy Yes 7 108 0.043
No 0 76
Focus Therapy 1 59 0.14
Prevention 3 100
Both 3 25
Main country Europe 1 25 1.00
America 6 159
Group Authorship Yes 6 155 1.00
No 1 29
Drug Intervention* Yes 2 50 1.00
No 5 134
Funding Govern-
ment
1 39 <0.001
Private 2 9
University 0 35
Other† 1 98
Mixed† 3 3
Authors ‡ 1-2 1 30 0.004
3-9 2 22
10-17 3 2
P-values are based on Fisher's exact test. * emphasis placed on medica-
tions rather than on vaccines, devices, surgical interventions, nutrition-
al interventions, counseling, screening, rehabilitation and other non-
pharmaceutical interventions † other sources of funding include mostly 
professional organizations (American College of Physicians, American 
Academy of Pediatrics, American Medical Association); mixed source 
of funding is defined as a combination of two or more of the four cat-
egories of funding ‡ n=60 for this analysis; 30 guidelines did not have 
group authorship and another 30 guidelines specified specific individu-
als who were primarily responsible for writing the manuscript, even if 
group authorship was mentioned
Table 2: Nature of potential conflicts disclosed
POTENTIAL CONFLICTS* N
Paid travel fees 7 (29%)
Provided consultation 5 (21%)
Received grants 3 (13%)
Received money as speakers 3 (13%)
Attended symposia 2 (8%)
Salary support 1 (4%)
Worked for a specific company 2 (8%)
Contract for a research project 1 (4%)
* Some authors disclosed more than one potential conflict of interestBMC Medical Research Methodology (2001) 1:3 http://www.biomedcentral.com/1471-2288/1/3
Conflicts of interest may not be reported either because
authors do not disclose them or because they are not
published by the journals. Furthermore, cases of incon-
sistency between stated journal policy and practice have
appeared in the recent literature [5].
It is estimated that the pharmaceutical industry in the
United States spends $8000 to $13000 per year on each
physician simply for marketing purposes [6,7] and this
phenomenon is probably international [8]. It is un-
known how these figures should be extrapolated to field
experts who are authors of clinical guidelines. More
studies are needed to examine the extent of financial and
other connections of experts to the industry in their field
of expertise. One study [9] found that 15% of lead au-
thors from Massachusetts publishing in 14 major bio-
medical journals in 1992 had at least one major potential
conflict of interest, such as serving on scientific advisory
boards of biotechnology firms in their state; being offic-
ers, directors or major shareholders in biotechnology
firms; or being listed as inventors in a relevant patent or
patent application. In all, 34% of the sampled articles
had at least one author with a financial conflict of inter-
est directly relevant to the publication [9]. The propor-
tion might have been larger if financial interest data
could have been retrieved from additional out-of-state
and international connections and if more non-financial
conflicts of interest could have been captured as well. In
another study of authors of 70 studies of calcium channel
blockers for treating cardiovascular disorders [10], 96%
of the authors of supportive studies had financial rela-
tionships with the manufacturers, as compared with
60% of neutral authors and 37% of critical authors. Only
2 of the 70 articles disclosed the authors' potential con-
flicts of interest. Finally, one study of faculty members at
the University of California [11] found that 7.6% of inves-
tigators reported personal financial ties with sponsors of
their research. Given the large heterogeneity in the poli-
cies of reporting faculty conflicts of interest [12,13], it is
difficult to arrive at exact estimates of the frequency of
serious competing interests in field experts.
In this study, it was not possible to determine exactly
what might have been undisclosed, since the authors
were sampled from all over the world and guidelines cov-
ered very diverse topics. Sorting out financial connec-
tions in a consistent fashion would have been practically
impossible. Non-financial conflicts of interest would be
even more intangible to the outsider. Nevertheless, one
may speculate that competing interests may have been at
least as common as what has been described in the other
studies mentioned above. For example, the 1999 BMJ
guideline about the management of hypertension [14]
did not declare any competing interests. In a MEDLINE
search, we were able to identify at least 66 randomized
controlled trials of anti-hypertensive interventions au-
thored by the guideline authors up to 1999 (range 1 to 34
per author). These trials evaluated a total of 27 different
anti-hypertensive drugs (range 0 to 14 per author) in var-
ious doses and formulations and 9 other non-pharma-
ceutical interventions. In any case, funding of trials by
the pharmaceutical industry does not mean that the in-
vestigators would be biased and it is expected that a pan-
el of leading scientists would be able to balance on
objective conclusions during the development of consen-
sus. Still, it would have been useful to know what might
have been the potential competing interests, including
non-financial ones [15], of the panel members.
We found that conflicts of interest were rarely, if ever,
published in clinical guideline reports funded by the gov-
ernment, universities or professional physician organi-
zations. Although it may be anticipated that such
sponsors may make more stringent efforts to assure ob-
jectivity in guideline development, it is still important
that potential conflicts of interest of the individuals par-
ticipating in the process should be acknowledged. This
holds true even if group authorship is assumed. Conflicts
of interest may be more worrisome when there is individ-
ual authorship. One would expect the objectivity of the
guideline to be more vulnerable when only one or two in-
dividuals are authoring it. Nevertheless, the likelihood of
disclosing conflicts of interest was smaller when few au-
thors took responsibility for a guideline than when sever-
al authors were involved.
Recent studies have focused on deficiencies in the devel-
opment and reporting of guidelines and have stressed
the need to standardize the process [16,17,18]. Conflicts
of interest can harm the credibility of guidelines. Com-
peting interests may negatively influence the quality of
clinical practice [19], as well as prescribing and profes-
sional behavior [6,8]. Even original studies [10] and
cost-effectiveness analyses [20] may reach differing re-
sults depending on competing interests. Clinical guide-
lines are likely to be even more vulnerable to these
influences.
Conclusions
Transparency, by means of disclosure of potential con-
flicts, could foster public trust. Such information would
take minimal space to report and may help to obviate
doubts regarding the integrity of clinical guidelines. Both
guideline authors and journal editors should pay more
attention to this important issue.
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